Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended October 31, 2006 (Six months ended October 31, 2006).
Business Stage: Development stage company focused on perfluorocarbon-based medical products, primarily "Oxycyte" (a synthetic blood substitute) and a glucose biosensor implant. The company is in pre-clinical and clinical trial stages with no commercial revenue.
Key Financial Metrics
| Metric | Three Months Ended Oct 31, 2006 | Six Months Ended Oct 31, 2006 | Balance Sheet (Oct 31, 2006) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(695,315) | $(1,406,385) | Accumulated Deficit: $(29,095,698) |
| Cash and Equivalents | N/A | N/A | $101,850 |
| Working Capital | N/A | N/A | $(661,589) (Negative) |
| Total Current Assets | N/A | N/A | $458,506 |
| Total Current Liabilities | N/A | N/A | $1,120,095 |
| Debt (Notes & Debentures) | N/A | N/A | $644,550 (Net of discounts) |
| Cash Flow from Operations | N/A | $(484,014) | N/A |
Material Changes vs. Prior Period
- Expense Reduction: Total expenses decreased by $995,192 for the three months and $876,340 for the six months compared to the prior year periods. This was driven by a significant reduction in General and Administrative (G&A) expenses due to a temporary cessation of operations and employee layoffs in October 2006.
- Net Loss Improvement: Net loss narrowed to $(695,315) for the quarter (vs. $(1,677,081) prior year) and $(1,406,385) for the six months (vs. $(2,289,429) prior year).
- Interest Expense: Interest expense decreased significantly ($703,625 for the quarter) due to reductions in interest costs and amortization of debt discounts.
- Liquidity Position: Cash and cash equivalents increased from $382 at the beginning of the period to $101,850, primarily due to financing activities (issuance of notes and stock).
Outlook, Risks, and Management Commentary
- Going Concern Doubt: Management states there is "substantial doubt" about the company's ability to continue as a going concern. The company lacks the working capital to fund operations for fiscal year 2007 and requires immediate financing.
- Operational Status: Operations were temporarily ceased, and employees were laid off in October 2006 to conserve resources while seeking financing.
- Clinical Trials:
- Oxycyte: Phase II enrollment in orthopedic surgery was put on hold due to slow enrollment (12 patients). A sickle cell anemia trial is on FDA clinical hold pending protocol changes. Estimated cost to complete Phase II trials is approximately $8,000,000.
- Other Products: Fluorovent and the glucose biosensor are not expected to file FDA applications for at least two years.
- Financing Needs: The company is actively seeking equity and/or debt financing. Failure to secure funding may force a complete cessation of operations.
- Stock-Based Compensation: The company adopted SFAS No. 123(R) effective May 1, 2006, resulting in recognized stock-based compensation expenses of $34,000 for the six months ended October 31, 2006.
Investor Verification Checklist
- Capital Sufficiency: Verify if the company has secured the immediate financing required to cover administrative expenses and restart clinical trials, given the negative working capital of $(661,589).
- Clinical Trial Status: Confirm the current status of the FDA clinical hold on the sickle cell anemia trial and the timeline for restarting the orthopedic surgery Phase II trial.
- Debt Obligations: Review the terms of the newly issued notes payable (9% and 18% interest rates) and the associated warrants to assess dilution and cash flow impact.
- Going Concern Opinion: Review the independent auditor's report for the fiscal year ended April 30, 2006, and any subsequent updates regarding the "substantial doubt" qualification.
- Related Party Transactions: Verify the terms of the $60,000 loan from an officer and payments to the specialty contract manufacturer where an officer is a minority shareholder.